N
Nykode Therapeutics ASA
OSE:NYKD
Nykode Therapeutics ASA
OSE:NYKD
Price:
3.084
NOK
3.14%
Market Closed
Market Cap:
kr1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
NO |
Income Statement
Earnings Waterfall
Nykode Therapeutics ASA
Nykode Therapeutics ASA
Income Statement
Nykode Therapeutics ASA
Nykode Therapeutics ASA
Currency: USD
| Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
+19%
|
0
N/A
|
0
N/A
|
0
-21%
|
0
+26%
|
0
N/A
|
0
-69%
|
0
N/A
|
(0)
N/A
|
(0)
N/A
|
(0)
-12%
|
215
N/A
|
215
+0%
|
217
+1%
|
218
+0%
|
34
-84%
|
34
+1%
|
36
+4%
|
35
-1%
|
7
-80%
|
10
+34%
|
11
+20%
|
14
+18%
|
13
-5%
|
11
-18%
|
6
-42%
|
4
-36%
|
9
+121%
|
8
-10%
|
7
-7%
|
7
-7%
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||
| Operating Expenses |
(3)
|
(5)
|
(6)
|
(7)
|
(7)
|
(6)
|
(5)
|
(3)
|
(13)
|
(11)
|
(17)
|
(25)
|
(34)
|
(40)
|
(43)
|
(47)
|
(42)
|
(46)
|
(50)
|
(59)
|
(58)
|
(69)
|
(72)
|
(69)
|
(69)
|
(70)
|
(65)
|
(63)
|
(56)
|
(48)
|
(42)
|
(33)
|
(29)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(6)
|
(4)
|
(7)
|
(10)
|
(16)
|
(19)
|
(19)
|
(19)
|
(18)
|
(14)
|
(15)
|
(18)
|
(19)
|
(23)
|
(25)
|
(26)
|
(28)
|
(30)
|
(30)
|
(32)
|
(32)
|
(26)
|
(23)
|
(18)
|
(14)
|
|
| Research & Development |
0
|
(2)
|
(3)
|
(3)
|
0
|
0
|
0
|
0
|
(7)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(16)
|
0
|
0
|
0
|
(27)
|
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Other Operating Expenses |
(2)
|
(1)
|
(1)
|
(1)
|
(4)
|
(2)
|
(2)
|
(3)
|
(0)
|
(6)
|
(10)
|
(14)
|
(7)
|
(21)
|
(24)
|
(27)
|
(7)
|
(31)
|
(34)
|
(40)
|
(10)
|
(44)
|
(45)
|
(41)
|
(9)
|
(38)
|
(32)
|
(29)
|
(22)
|
(20)
|
(17)
|
(13)
|
(13)
|
|
| Operating Income |
(3)
N/A
|
(5)
-54%
|
(6)
-13%
|
(7)
-16%
|
(7)
+4%
|
(6)
+4%
|
(5)
+20%
|
(3)
+35%
|
(13)
-302%
|
(11)
+16%
|
(17)
-55%
|
(25)
-43%
|
181
N/A
|
175
-3%
|
174
-1%
|
171
-2%
|
(8)
N/A
|
(12)
-54%
|
(14)
-21%
|
(24)
-66%
|
(51)
-110%
|
(59)
-17%
|
(61)
-3%
|
(55)
+9%
|
(56)
-2%
|
(59)
-5%
|
(59)
+0%
|
(60)
-1%
|
(47)
+21%
|
(40)
+14%
|
(35)
+13%
|
(26)
+25%
|
(29)
-8%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
0
|
1
|
0
|
(0)
|
0
|
(0)
|
1
|
2
|
5
|
7
|
8
|
14
|
10
|
11
|
12
|
3
|
8
|
11
|
10
|
13
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
(2)
|
|
| Pre-Tax Income |
(3)
N/A
|
(5)
-56%
|
(6)
-16%
|
(7)
-17%
|
(6)
+4%
|
(6)
+2%
|
(5)
+20%
|
(3)
+35%
|
(14)
-326%
|
(10)
+27%
|
(16)
-63%
|
(24)
-45%
|
181
N/A
|
176
-3%
|
175
-1%
|
172
-2%
|
(11)
N/A
|
(11)
-3%
|
(15)
-29%
|
(23)
-58%
|
(51)
-118%
|
(54)
-7%
|
(54)
+1%
|
(47)
+13%
|
(44)
+6%
|
(49)
-10%
|
(48)
+2%
|
(48)
-1%
|
(46)
+6%
|
(33)
+28%
|
(25)
+25%
|
(17)
+33%
|
(18)
-6%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(31)
|
(29)
|
(28)
|
(25)
|
2
|
2
|
2
|
4
|
8
|
8
|
7
|
5
|
9
|
9
|
10
|
11
|
7
|
7
|
7
|
6
|
5
|
|
| Income from Continuing Operations |
(3)
|
(5)
|
(6)
|
(7)
|
(6)
|
(6)
|
(5)
|
(3)
|
(14)
|
(10)
|
(16)
|
(24)
|
150
|
146
|
146
|
147
|
(9)
|
(10)
|
(12)
|
(20)
|
(43)
|
(46)
|
(47)
|
(42)
|
(35)
|
(40)
|
(38)
|
(37)
|
(39)
|
(25)
|
(17)
|
(11)
|
(12)
|
|
| Net Income (Common) |
(3)
N/A
|
(5)
-56%
|
(6)
-16%
|
(7)
-17%
|
(6)
+4%
|
(6)
+2%
|
(5)
+20%
|
(3)
+35%
|
(14)
-326%
|
(10)
+27%
|
(16)
-63%
|
(24)
-45%
|
150
N/A
|
146
-2%
|
146
+0%
|
147
+0%
|
(9)
N/A
|
(10)
-4%
|
(12)
-26%
|
(20)
-60%
|
(43)
-116%
|
(46)
-8%
|
(47)
-1%
|
(42)
+10%
|
(35)
+16%
|
(40)
-13%
|
(38)
+5%
|
(37)
+1%
|
(39)
-4%
|
(25)
+35%
|
(17)
+33%
|
(11)
+36%
|
(12)
-11%
|
|
| EPS (Diluted) |
-0.06
N/A
|
-0.09
-50%
|
-0.11
-22%
|
-0.13
-18%
|
-0.11
+15%
|
-0.12
-9%
|
-0.09
+25%
|
-0.06
+33%
|
-0.25
-317%
|
-0.18
+28%
|
-0.3
-67%
|
-0.09
+70%
|
0.51
N/A
|
0.44
-14%
|
0.68
+55%
|
0.59
-13%
|
-0.03
N/A
|
-0.04
-33%
|
-0.04
N/A
|
-0.06
-50%
|
-0.15
-150%
|
-0.16
-7%
|
-0.16
N/A
|
-0.14
+12%
|
-0.12
+14%
|
-0.13
-8%
|
-0.12
+8%
|
-0.12
N/A
|
-0.12
N/A
|
-0.07
+42%
|
-0.05
+29%
|
-0.03
+40%
|
-0.04
-33%
|
|
Switch to:
Switch to:
See Also
Discover More
